Financial Data and Key Metrics Changes - The underlying EPS for Q3 2025 was $1.86, reflecting a 6% year-over-year increase [5] - Underlying net income reached $1.047 billion, up 3% year-over-year [17] - The underlying ROE was 18.3%, showing progress towards medium-term objectives [5][18] - Book value per share increased by 3% quarter-over-quarter [5] - The LICAT ratio stood at 154%, indicating a strong capital position [9][19] Business Line Data and Key Metrics Changes - Individual protection sales grew by 35%, while group health and protection sales increased by 12% [5] - Health and protection underlying earnings decreased by 18% year-over-year due to unfavorable insurance experience in the U.S. [17] - Individual protection underlying net income rose by 25% year-over-year, driven by favorable mortality experience in Asia and higher investment earnings in Canada [17] - Asset management and wealth underlying earnings increased by 5% year-over-year [17] Market Data and Key Metrics Changes - In Asia, individual protection sales saw double-digit growth in six markets, with new business CSM growing by 20% year-over-year [8] - Canada reported a 13% increase in net income, driven by strong business growth and favorable insurance experience [24] - U.S. group health and protection sales increased by 25% year-over-year, driven by higher large case sales [25] Company Strategy and Development Direction - The company aims for a medium-term objective of 10% underlying earnings growth, 20% ROE, and dividend payouts in the range of 40-50% of underlying earnings [15] - The focus remains on improving U.S. dental business performance through repricing and growth of the commercial business [8] - The company is committed to leveraging its asset management capabilities to support growth in insurance and wealth businesses [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the U.S. business due to structural changes in the healthcare system, leading to higher claims frequency and costs [6] - Confidence was expressed in the ability to manage pricing and risk selection despite current challenges [8][15] - The company anticipates gradual improvement in the U.S. dental business as pricing adjustments are made [60] Other Important Information - The company announced a $0.04 increase in its dividend to $0.92 per share and repurchased approximately $400 million of shares in the quarter [9] - Total CSM increased by 12% year-over-year to $14.4 billion, driven by strong organic growth [19] Q&A Session Summary Question: Expectations for Medicaid repricing in 2026 - Management is making reasonable progress with states regarding pricing, expecting gradual improvements in 2026 [32] Question: Growth in U.S. commercial premiums - Premiums have grown more than 30% since the acquisition, with a focus on packaging commercial dental with group benefits [34] Question: Asset management flows and institutional progress - The company acknowledges lumpiness in flows but sees long-term growth potential, particularly in international strategies [38][41] Question: Details on unfavorable stop loss experience - Unfavorable experience was attributed to pricing shortfalls and late emergence of claims, with updates to loss ratio picks reflecting this [45][46] Question: Outlook for Medicaid dental loss ratio - Management expects gradual improvement in loss ratios moving into 2026, with Q4 typically being more favorable [60] Question: Potential for a smaller business in 2026 - Management is confident in their plans and distribution network, expecting to grow the business over time despite current adjustments [88]

Financial Data and Key Metrics Changes - The underlying EPS for Q3 2025 was $1.86, reflecting a 6% increase year over year [4][16] - Underlying net income reached $1.047 billion, up 3% from the previous year [16] - The underlying return on equity (ROE) was 18.3%, an increase from the prior year [17] - Book value per share grew 2% year over year, with a quarterly increase of 3% [19] Business Line Data and Key Metrics Changes - Individual protection sales increased by 35%, while group health and protection sales grew by 12% [4] - Health and protection underlying earnings decreased by 18% year over year due to unfavorable insurance experience in the U.S. [16] - Asset management and wealth underlying earnings rose by 5% year over year, driven by improved credit and higher fee income [16] - SLC Management's underlying net income was $54 million, up 15% year over year [21] Market Data and Key Metrics Changes - In Asia, individual protection sales grew by 38% year over year, with double-digit growth in six markets [26] - Canada reported net income of $422 million, a 13% increase from the prior year, driven by strong business growth [22] - U.S. underlying net income was $107 million, down 34% from the previous year, primarily due to unfavorable insurance experience [23] Company Strategy and Development Direction - The company aims for a medium-term objective of 10% underlying earnings growth and a 20% ROE [13] - Focus on improving U.S. dental business performance through repricing and growth of the commercial business [6] - Continued investment in asset management capabilities, with a target of leveraging synergies between asset management and insurance businesses [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating industry challenges, particularly in the U.S. health care space [5] - The company anticipates gradual improvement in the U.S. dental business as pricing adjustments are made [6] - Strong fundamentals and diversified business mix are expected to support continued growth [26] Other Important Information - The company announced a $0.04 increase in its dividend to $0.92 per share and repurchased approximately $400 million of shares in the quarter [7] - The LICAT ratio was reported at 154%, indicating a strong capital position [7] Q&A Session Summary Question: Expectations for Medicaid repricing starting in 2026 - Management is making reasonable progress with states on pricing, with gradual improvements expected in 2026 [36] Question: Growth in U.S. commercial premiums - Premiums have grown over 30% since the acquisition, with expectations for continued growth in commercial dental [38] Question: Details on asset management flows - The company noted lumpiness in flows but highlighted significant institutional gross sales and positive net inflows in public fixed income and active ETFs [42][46] Question: Unfavorable insurance experience in medical stop loss - The unfavorable experience was attributed to pricing shortfalls and late emergence of claims, with updates to loss ratio assumptions being made [54][58] Question: Outlook for Medicaid dental loss ratio - Management expects gradual improvement in the loss ratio as pricing adjustments are implemented [69] Question: Targeted return of 7% in stop loss - The current after-tax margin was reported at 6.9%, with expectations to move towards the targeted margin over time [108]